Fate Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Fate Therapeutics

04/08/2021 22:44

* Fate Therapeutics Inc  FATE.OQ  reported a quarterly adjusted
loss of 58 cents​​ per share for the quarter ended in June. The
mean expectation of fifteen analysts for the quarter was for a
loss of 53 cents per share.
* Revenue rose 145.4% to $13.41 million from a year ago; 
analysts expected $6.31 million. 
* Fate Therapeutics Inc's reported EPS for the quarter was a
loss of 58 cents​.
* The mean earnings estimate of analysts had fallen by
about 10.2% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Fate Therapeutics Inc shares had fallen by 4.1% this
quarter and lost 8.4% so far this year.
* The company reported a quarterly loss of $55.13 million.
* Wall Street's median 12-month price target for Fate
Therapeutics Inc is $115.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 13 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 4 at 09:44 p.m.  ​All
figures in US dollars unless otherwise stated